menu
    • menu

    Company profile for BioVersys AG

    NEW Drugs in Dev: 7
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    The Swiss biopharmaceutical company BioVersys focuses on research and development of small molecules which switch off drug resistance against existing antibiotics. With the company’s award-winning TRIC technology (Transcriptional Regulator Inhibitory Compounds) it will be possible to restore the efficacy of established antibiotics. By this, BioVersys addresses the high medical need for new treatments against life-threatening...
    The Swiss biopharmaceutical company BioVersys focuses on research and development of small molecules which switch off drug resistance against existing antibiotics. With the company’s award-winning TRIC technology (Transcriptional Regulator Inhibitory Compounds) it will be possible to restore the efficacy of established antibiotics. By this, BioVersys addresses the high medical need for new treatments against life-threatening bacterial infections that emerged in recent years due to the resistance of bacterial strains against existing antibiotics.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    BioVersys AGSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Hochbergerstrasse 60c c/o Technologiepark CH-4057 Basel
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.bioversys.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/bioversys-ag
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/bioversys?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nature Communications Reveals Alpibectir's Unique Action
    Nature Communications Reveals Alpibectir's Unique Action

    13 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/13/3272190/0/en/Data-Published-in-Nature-Communications-Highlights-Unique-Mechanism-of-Action-of-Alpibectir-in-Combination-with-Ethionamide-AlpE.html

    GLOBENEWSWIRE
    13 Apr 2026
    Share Share
    BioVersys Highlights 2025 Corporate Results
    BioVersys Highlights 2025 Corporate Results

    18 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/18/3257882/0/en/BioVersys-Reports-Corporate-Highlights-and-Financial-Results-for-the-Full-Year-2025.html

    GLOBENEWSWIRE
    18 Mar 2026
    Share Share
    FDA Clears BioVersys BV100 for Phase 3 HABP/VABP Trials
    FDA Clears BioVersys BV100 for Phase 3 HABP/VABP Trials

    16 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/16/3255983/0/en/BioVersys-Receives-Green-Light-from-US-FDA-for-BV100-HABP-VABP-Phase-3-Pivotal-Trial-Start.html

    GLOBENEWSWIRE
    16 Mar 2026
    Share Share
    BioVersys Doses First Patient in Phase 2b AlpE Pulmonary TB Trial
    BioVersys Doses First Patient in Phase 2b AlpE Pulmonary TB Trial

    13 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/12/3254275/0/en/BioVersys-Announces-First-Patient-Dosed-in-Phase-2b-Clinical-Trial-of-AlpE-in-Pulmonary-Tuberculosis.html

    GLOBENEWSWIRE
    13 Mar 2026
    Share Share
    BioVersys Reports 2025 Results, Provides Update and Hosts Call
    BioVersys Reports 2025 Results, Provides Update and Hosts Call

    05 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/05/3249840/0/en/BioVersys-to-Report-Its-Full-Year-2025-Financial-Results-Provide-a-Business-Update-and-Host-a-Conference-Call.html

    GLOBENEWSWIRE
    05 Mar 2026
    Share Share
    BioVersys Announces Publication of BV100 Ph1 Data in Journal
    BioVersys Announces Publication of BV100 Ph1 Data in Journal

    04 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/04/3249041/0/en/BioVersys-Announces-Publication-of-BV100-Phase-1-Clinical-Data-in-Journal-of-Antimicrobial-Agents-and-Chemotherapy.html

    GLOBENEWSWIRE
    04 Mar 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search